

Optomed Q4 - Quarter in line with expectations

Redeye provides an update following Optomed's Q4 report. The report fairly aligned with our expectations as sales were in line with our estimate. However, we make some downward sales estimate changes throughout our forecast and incorporate a new WACC, rendering an updated fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Optomed Q4 - Quarter in line with expectations